Shigella News and Research

RSS

Scientists discover new genetic information linked with shigellosis

Scientists have found new genetic information that shows how harmful bacteria cause the acute diarrheal disease shigellosis, which kills more than a million people worldwide each year.

12 Jun 2012

USPTO issues two patents on 'Novel Shigella protein antigens and methods' to IVI

The International Vaccine Institute (IVI), an international organization based in Seoul devoted to research on the development and introduction of vaccines for the developing world, reached a milestone in its aim to prevent and control dysentery (also commonly called shigellosis or bloody diarrhea), a deadly disease that affects several million people worldwide.

27 Feb 2012

APUA applauds FDA for acting to limit antibiotics in food-producing animals

The Alliance for the Prudent Use of Antibiotics (APUA) today praised the U.S. Food and Drug Administration (FDA) for acting to limit certain extra label uses of cephalosporins in major animal species – cattle, swine, chickens and turkeys – where misuse and overuse are cause for great concern. Extra label use occurs when use of a drug does not comply with the approved labeling.

6 Jan 2012

Novel antibacterial protein could prevent or treat E. coli O157:H7-induced food-borne infections

A novel antibacterial protein targeted against E. coli O157:H7 may offer a way to prevent or treat serious food-borne bacterial infections, as demonstrated in a study published in the December issue of Antimicrobial Agents and Chemotherapy.

21 Nov 2011

Avidocin protein could prevent or treat E. coli O157:H7-induced diarrhea

21 Nov 2011

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

Although outbreaks are rare, Ebola virus, the cause of Ebola hemorrhagic fever (EHF), is one of the deadliest known viruses affecting humans. According to the World Health Organization (WHO), approximately 1,850 EHF cases with more than 1,200 deaths have been documented since the virus was identified in 1976.

25 Aug 2011

GlycoVaxyn's Second Annual Science Day to highlight challenges of vaccine industry

GlycoVaxyn AG, a leader in the development of conjugate vaccines, today announced that it will host its Second Annual Science Day to discuss challenges and opportunities in vaccine development on June 16-17, 2011, in Cannes, France.

15 Jun 2011

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

Diarrheal disease, a common gastrointestinal problem with potentially fatal implications in the developing world is the focus of World Digestive Health Day on May 29. Infections that cause diarrhea are serious public health challenges, both in the United States and globally.

27 May 2011

Affymetrix launches new menu of multiple genomic microarray tools

Affymetrix, Inc. today announced the availability of multiple genomic microarray tools that will further enable scientists in the applied research field.

18 May 2011

World Health Day 2011 highlights problem of antimicrobial resistance

On the eve of World Health Day 2011, Inter Press Service examines the growing global challenge of antibimicrobial resistance.

7 Apr 2011

Scientists show how E. coli strain causes infection in individuals

Scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have shown how the O157:H7 strain of Escherichia coli causes infection and thrives by manipulating the host immune response.

15 Mar 2011

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

Anacor Pharmaceuticals (NASDAQ:ANAC) and the Institute for OneWorld Health (iOWH) today announced the establishment of a joint research agreement to discover antibacterial compounds for treating shigellosis.

8 Mar 2011

First chromogenic culture medium to simultaneously detect Salmonella and Shigella

Hardy Diagnostics, an ISO certified biomedical firm, is pleased to announce the release of HardyCHROM™ SS, a highly selective chromogenic medium recommended for use as a primary screening medium for the isolation and differentiation of Salmonella and Shigella spp. from stool cultures. These two pathogens can be easily distinguished from non-pathogenic enteric bacteria based on colony color.

14 Feb 2011

T3SS-dependent bacteria may be a suitable point of attack for future antibiotics: Study

So-called type-3 secretion systems of pathogenic bacteria may be a suitable point of attack for future antibiotics. This is shown by Professor Maria Fällman and her associates at Umeå University in Sweden in the Proceeding of the National Academy of Sciences, PNAS, in the US.

18 Jan 2011

VBI researchers receive grant to study immune responses to gut pathogens

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a $10.6 million grant to researchers at the Virginia Bioinformatics Institute (VBI) and collaborators to determine how the human immune system responds to infection by pathogens of the gut. The funding will be used to apply mathematical modeling to the study of immune responses to gut pathogens.

11 Oct 2010

Phase I study of Shigella dysenteriae bioconjugate vaccine meets primary, secondary endpoints

GlycoVaxyn AG, a leader in the development of innovative vaccines, announced today that the Phase I study of its Shigella dysenteriae bioconjugate vaccine has been completed and met the primary and secondary endpoints: demonstration of safety and immunogenicity.

8 Oct 2010

Mucosis collaborates with PATH to pursue use of Mimopath technology in diarrhea vaccines

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company's Mimopath technology in oral vaccines to prevent and treat severe diarrhea.

28 Sep 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

GlycoVaxyn AG, a leader in the development of innovative bioconjugate vaccines, and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, announced today that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine. S. aureus is a major cause of hospital-based infections.

4 May 2010

Breast-feeding may help lower risk of death from Shigella infection in developing countries: Study

Teaching parents about the importance of continued breast-feeding may help to lower the risk of death from brain disease (encephalopathy) related to Shigella infection in developing countries, reports a study in the May issue of The Pediatric Infectious Disease Journal.